Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal
- PMID: 21987539
- DOI: 10.1177/0272989X11416870
Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal
Abstract
Background: Health care decision making is complex and requires efficient and explicit processes to ensure transparency and consistency of factors considered.
Objectives: To pilot an adaptable decision-making framework incorporating multicriteria decision analysis (MCDA) in health technology assessment (HTA) with a pan-Canadian group of policy and clinical decision makers and researchers appraising 10 medicines covering 6 therapeutic areas.
Methods: An appraisal group was convened and participants were asked to express their individual perspectives, independently of the medicines, by assigning weights to each criterion of the MCDA core model: disease severity, size of population, current practice and unmet needs, intervention outcomes (efficacy, safety, patient reported), type of health benefit, economics, and quality of evidence. Participants then assigned performance scores for each medicine using available evidence synthesized in a "by-criterion" HTA report covering each of the MCDA CORE model criteria. MCDA estimates of perceived value were calculated by combining normalized weights and scores. Feedback on the approach was collected through structured discussion.
Results: Relative weights on criteria varied widely, reflecting the diverse perspectives of participants. Scores for each criterion provided a performance measure, highlighting strengths and weaknesses of each medicine. MCDA estimates of perceived value ranged from 0.42 to 0.64 across medicines, providing comprehensive measures incorporating a large spectrum of criteria. Participants reported that the framework provided an efficient approach to systematic consideration in a pragmatic format of the multiple elements guiding decision, including criteria and values (MCDA core model) and evidence (HTA "by-criterion" report).
Conclusions: This proof-of-concept study demonstrated the usefulness of incorporating MCDA in HTA to support transparent and systematic appraisal of health care interventions. Further research is needed to advance MCDA-based approaches to more effective healthcare decision making.
Similar articles
-
Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada.BMC Health Serv Res. 2011 Nov 30;11:329. doi: 10.1186/1472-6963-11-329. BMC Health Serv Res. 2011. PMID: 22129247 Free PMC article.
-
Multicriteria decision analysis (MCDA) for health technology assessment: the Queensland Health experience.Aust Health Rev. 2019 Oct;43(5):591-599. doi: 10.1071/AH18042. Aust Health Rev. 2019. PMID: 30205873
-
Impact on decision making framework for medicine purchasing in Chinese public hospital decision-making: determining the value of five dipeptidyl peptidase 4 (DPP-4) inhibitors.BMC Health Serv Res. 2021 Aug 12;21(1):807. doi: 10.1186/s12913-021-06827-0. BMC Health Serv Res. 2021. PMID: 34384428 Free PMC article.
-
Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.Health Technol Assess. 2010 May;14(25):iii-iv, ix-xii, 1-107. doi: 10.3310/hta14250. Health Technol Assess. 2010. PMID: 20501062 Review.
-
Balancing costs and benefits at different stages of medical innovation: a systematic review of Multi-criteria decision analysis (MCDA).BMC Health Serv Res. 2015 Jul 9;15:262. doi: 10.1186/s12913-015-0930-0. BMC Health Serv Res. 2015. PMID: 26152122 Free PMC article. Review.
Cited by
-
An innovative tool to prioritize the assessment of investigational COVID-19 therapeutics: A pilot project.Can Commun Dis Rep. 2024 Oct 3;50(10):357-364. doi: 10.14745/ccdr.v50i10a04. eCollection 2024 Oct. Can Commun Dis Rep. 2024. PMID: 39380802 Free PMC article.
-
The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD).Orphanet J Rare Dis. 2024 Aug 23;19(1):308. doi: 10.1186/s13023-024-03324-5. Orphanet J Rare Dis. 2024. PMID: 39180132 Free PMC article.
-
Using a Patient-Centered Multicriteria Decision Analysis to Assess the Value of Multiple Sclerosis Treatments in the US: A Study Protocol.Pharmacoecon Open. 2024 Sep;8(5):773-781. doi: 10.1007/s41669-024-00509-3. Epub 2024 Jul 9. Pharmacoecon Open. 2024. PMID: 38982030 Free PMC article.
-
Evaluating vonoprazan and tegoprazan for gastroesophageal reflux disease treatment in Chinese Healthcare: an EVIDEM framework analysis.BMC Gastroenterol. 2024 Jun 20;24(1):208. doi: 10.1186/s12876-024-03297-6. BMC Gastroenterol. 2024. PMID: 38902604 Free PMC article.
-
Determining value in the treatment of activated PI3Kδ syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders.Glob Reg Health Technol Assess. 2024 May 22;11:124-130. doi: 10.33393/grhta.2024.3041. eCollection 2024 Jan-Dec. Glob Reg Health Technol Assess. 2024. PMID: 38784663 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
